This was further corroborated by findings demonstrating that co-treatment with MI and pan-BETi (OTX015) or BD2-selective BETi (ABBV-744), or LSD1i, synergistically induced in vitro loss of viability not only of AML cell lines but also PD AML cells that harbor either MLL1-r or mtNPM1 along with FLT3-ITD and/or mtFLT3 (TKD). This evidence concerns the gene KMT2A and acute myeloid leukemia.